IL-1R2 promotes tumorigenesis and modulates the tumor immune microenvironment in colorectal cancer
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04138-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Yanyan Lang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Jiangsu, 213003, Changzhou, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Colorectal Neoplasms, Receptors, Interleukin-1 Type II, Carcinogenesis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Provincial-level Talent Program for National Center of Technology Innovation for Biopharmaceuticals, National Natural Science Foundation of China, the Key R&D Project of Jiangsu Province.
Abstract (Originalsprache)
Colorectal cancer (CRC) continues to be a major global health challenge due to its high incidence and mortality rates, emphasizing the critical need for innovative therapeutic strategies. IL-1R2, a member of the IL-1 receptor family, plays a pivotal role in both tumorigenesis and antitumor immunity. However, its precise role in tumor development and its impact on immune checkpoint inhibitors (ICIs) therapy in CRC remain poorly understood. We examined tumor progression in wild-type and IL-1R2-deficient mice using an AOM/DSS-induced colitis-associated colorectal cancer model treated with combined ICIs therapy. Our findings revealed that IL-1R2 deficient mice exhibited a significant reduction in tumor burden, accompanied by alterations in the carcinogenic program and enhanced immunogenicity of tumor cells. Furthermore, the deletion of IL-1R2 resulted in an increased proportion of exhausted CD8 + T cells, a population commonly enriched for tumor antigen-specific T cells, suggesting an augmentation of tumor-specific immune responses. Moreover, IL-1R2 deletion upregulated genes linked to antigen presentation in dendritic cells, indicating enhanced activation of the adaptive immune system. Collectively, these findings position IL-1R2 as a promising therapeutic target for improving the efficacy of treatment strategies in CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Jiangsu, 213003, Changzhou, China.
- Jiangsu Engineering Research Center for Tumor Immunotherapy, The Third Affiliated Hospital of Soochow University, Jiangsu, 213003, Changzhou, China.
- Institute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Jiangsu, 213003, Changzhou, China.
- Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Jiangsu, 213003, Changzhou, China. jiangjingting@suda.edu.cn.
- Jiangsu Engineering Research Center for Tumor Immunotherapy, The Third Affiliated Hospital of Soochow University, Jiangsu, 213003, Changzhou, China. jiangjingting@suda.edu.cn.
- Institute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Jiangsu, 213003, Changzhou, China. jiangjingting@suda.edu.cn.
Förderung
- Provincial-level Talent Program for National Center of Technology Innovation for Biopharmaceuticals
- National Natural Science Foundation of China
- the Key R&D Project of Jiangsu Province
- Jiangsu Provincial Medical Key Discipline
- Changzhou Clinical Medical Center
- Prospective Research Program of Changzhou Xitaihu Development Foundation For Frontier Cell-Therapeutic Technology
- Top Talent of Changzhou ‘The 14th Five-Year Plan’ High-Level Health Talents Training Project
Zitieren
APA
Lang, Y., Huang, H., Jiang, H., Wu, S., Fang, Z., Zhang, D., Qian, H., Liu, Y., Yuan, M., Xu, B., Chen, L., Zheng, X., & Jiang, J. (2025). IL-1R2 promotes tumorigenesis and modulates the tumor immune microenvironment in colorectal cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04138-5
Vancouver
Lang Y, Huang H, Jiang H, Wu S, Fang Z, Zhang D, et al. IL-1R2 promotes tumorigenesis and modulates the tumor immune microenvironment in colorectal cancer. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04138-5
BibTeX
@article{Lang2025,
author = {Lang, Yanyan and Huang, Hao and Jiang, Hongwei and Wu, Shaoxian and Fang, Zhang and Zhang, Dachuan and Qian, Heya and Liu, Yingting and Yuan, Maoling and Xu, Bin and Chen, Lujun and Zheng, Xiao and Jiang, Jingting},
title = {IL-1R2 promotes tumorigenesis and modulates the tumor immune microenvironment in colorectal cancer},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04138-5}
}
EUVIMED